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Others have studied acupuncture treatment for polycystic ovary syndrome (PCOS). Anti-müllerian hormone (AMH) is positively
correlated with the ovarian follicle pool, thus making it a useful ovarian reserve measure. AMH is elevated in women with PCOS
and has been suggested as a diagnostic tool. This study examined the impact of electroacupuncture on AMH concentration in
women with PCOS. Seventy-one women with PCOS participated in a randomized, double-blind, sham-controlled clinical trial of
acupuncture. Three longitudinal AMH samples over the 5-month protocol were compared with objective ovulation parameters
primarily using nonparametric statistics. Results indicated that AMH levels in PCOS were higher than published norms in women
without PCOS. There was no difference between the true and sham acupuncture arms in the change in AMH longitudinally.
Baseline AMH, but not the change in AMH over time, was inversely correlated with ovulation and menstrual cycle frequencies in
both arms combined (P < 0.001). In conclusion, AMH correlated with an increased likelihood of monthly ovulation, as expected
from the literature on women without PCOS. The lack of difference by intervention in AMH was consistent with the underlying
clinical trial. AMH may be clinically useful to predict which PCOS women are more likely to respond to an intervention.
1. Introduction
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder in women of reproductive age with
incidence ranging from 8.7% to 17.8% depending upon
which criteria are used [1]. Diagnosis of PCOS is made when
androgen excess, ovulatory dysfunction, and/or polycystic
ovaries are identified after the exclusion of other disorders
that can cause these signs and symptoms [2]. Although
not a part of the formal diagnosis, a number of endocrine
abnormalities are often seen, including an increased ratio of
luteinizing hormone (LH) to follicle stimulating hormone
(FSH) [3] and insulin resistance [4]. There is emerging
evidence that serum anti-müllerian hormone (AMH) may be
useful in the diagnosis of PCOS [5].
AMH is expressed by the ovarian preantral and early
antral follicles and reflects the size of the follicular pool.
AMH levels gradually decline as the follicle pool declines,
and it is thus useful as a marker of ovarian reserve, although
there is no consensus on a threshold value for diagnosis of
diminished ovarian reserve [6–8].
Emerging evidence has linked elevated AMH levels with
women who have PCOS. AMH concentration correlates well
with clinical, endocrine, and ultrasound markers associated
with PCOS and may be a useful marker for the extent of
disease [5, 9]. Although growing data support AMH as a
possible clinical diagnostic and/or prognostic marker, there
is little known about changes in AMH level in response to an
intervention.
Acupuncture has been shown to be efficacious for
a number of medical conditions. Of women seen in a
reproductive endocrinology and infertility clinic, 22% had
tried acupuncture therapy within 18 months of their initial
clinic visit in the USA [10] and 12.5% within 6 months in
Australia [11]. Researchers found an 8% use of acupuncture
among infertility patients in the UK [12]. Interestingly, we
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found no difference in ovulation rates or ovarian hormones
levels between the active acupuncture and sham acupuncture
arms of a randomized clinical trial, although there was
a suggestion that both arms benefited from improved
frequency of ovulation during the study [13].
Given these results, we set out through a secondary
analysis of a randomized clinical trial to determine if AMH
levels can predict response to acupuncture and/or can predict
ovulation among oligoovulatory and anovulatory untreated,
adult female patients with PCOS. Additionally, we aimed
to characterize the levels of AMH of this subset of women
relative to women without PCOS by age, as reported by
others.
2. Materials and Methods
2.1. Population. This is a secondary analysis of AMH results
from a randomized, double-blind, sham-controlled clinical
trial of acupuncture in women diagnosed with PCOS.
The original trial is described in detail elsewhere [13]. In
summary, the 5-month protocol involved baseline question-
naires and biological sampling, 2 intervention months, post-
intervention repeat questionnaires and biological sampling,
3 months of follow-up without intervention, and post-
follow-up questionnaires and biological sampling. Women
provided urine or blood samples weekly throughout the
entire 5 months for objective assessment of ovulation.
Menses were self-reported. This trial was approved by the
University of Virginia’s Institutional Review Board (no.
12045).
Inclusion criteria were (a) a diagnosis of PCOS, as
confirmed by the presence of both oligomenorrhea and
hyperandrogenism per the US National Institutes of Health
criteria [14], (b) aged 18 to 43 years, (c) at least one
menses in the past six months but no more than eight
periods in the most recent 12 months without hormonal
intervention, and (e) agreement to not take hormonal
contraceptives, metformin, or fertility medication for the 5
months of study participation. Exclusion criteria were (a)
diagnosed with Cushing’s Syndrome, uncontrolled thyroid
disease, hyperprolactinemia, congenital adrenal hyperplasia,
and diabetes mellitus, (b) use of metformin or hormonal
contraceptives in the 60 days prior to enrollment, (c) use of
any other hormonal drug in the 30 days prior to entry into
study, including fertility medications, and over-the-counter
hormonal supplements or herbs (i.e., black cohosh, clover,
soy, dong quai/Chinese angelica root, fructus rubi, and
white peony root), (d) currently pregnant or breastfeeding
during the prior 30 days, (e) any acupuncture treatment
for ovulatory disorders in the prior 30 days, (f) weight >
113.4 kg (250 pounds), (g) currently taking anticoagulation
medication other than low-dose (≤81 mg) aspirin, (h)
immune deficient, and (i) history of any bleeding disorder.
2.2. Interventions and Ovulation Assessment. Subjects were
randomized to 12 acupuncture or sham sessions: twice each
week for the first four weeks followed by once per week
for an additional four weeks. For the true acupuncture
treatment, the following bilateral points were stimulated
with electroacupuncture (EA): Bladder 23, Bladder 28,
Spleen 6, and Spleen 9. The following points were manually
stimulated: Pericardium 6, Triple Energizer 5, and Governor
Vessel 20. The sham acupuncture was performed with the
validated Park Sham Device [15, 16]. The sham device
was placed on the skin at standardized points on all four
extremities (Achilles tendon and lateral head of the triceps)
chosen in order to avoid standard acupuncture meridians
and acupuncture points [17]. For further details, the reader
is referred to a prior publication [13].
The participants provided weekly blood samples for
serum progesterone measurement or collected first-void
urine samples at home (stored in their home freezer)
for pregnanediol glucuronide (PDG) measurement, for the
entire 5-month protocol. Ovulation was defined as proges-
terone ≥3 ng/mL or a ratio of the peak urinary PDG to the
basal PDG level in the follicular phase ≥4.0.
2.3. AMH Assays. Serum AMH was measured longitudinally
on all study participants using samples collected at their three
study center visits (preintervention, postintervention, and
after 3 months of follow-up). The assays were conducted
by the Clinical Laboratory Research Core at Massachusetts
General Hospital (Boston, MA, USA) using an AMH Gen
II ELISA kit from Beckman Coulter according to the
manufacturer’s protocol. The sensitivity of the assay was
0.05 ng/mL.
2.4. Statistical Analyses. Medians and interquartile ranges
were calculated by intervention arm, rather than means and
standard deviations, due to the modest sample size. Graphs
were created to investigate the distributions. Potential dif-
ferences between the intervention arms were assessed with
Kruskal Wallis, Wilcoxon Rank Sum, or Sign tests (contin-
uous variables) and Spearman chi-square tests (categorical
variables). After zero-skewness log transformation of AMH,
linear regression was used to develop lines-of-best fit. t-tests
were used to compare this cohort to the literature. Power
calculations were not run a priori due to the fact that this
was a secondary analysis. Statistical significance was judged
by a two-sided alpha≤ 0.05, unless otherwise specified.
All statistical analyses were conducted with STATA/IC 12
software (STATA Corp, TX, USA).
3. Results
Ninety-six women were eligible, consented, and were ran-
domized for the underlying acupuncture clinical trial [13],
and 72 had more than one AMH sample as required
for this longitudinal analysis. Of those 72 women, one
was subsequently dropped from the dataset due to peri-
menopausal AMH levels (<0.05 mg/mL) despite a normal
FSH level at baseline (2.7 mIU/mL) (Figure 1). Of the final
cohort of 71 women diagnosed with PCOS, 32 received
active acupuncture and 39 received sham acupuncture. These
women were randomized between February 2006 and August
2009.
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134 completed PCOS screening
38 excluded from acupuncture RCT
28 did not meet eligibility criteria
10 eligible and declined to participate
24 excluded due to only 1 AMH sample
1 excluded due to perimenopausal
AMH values
Sham treatment arm (n = 39)
with longitudinal AMH data
Acupuncture treatment arm (n = 32)
with longitudinal AMH data
96 randomized =
80 completed the protocol
5 withdrew after the intervention
11 withdrew during the intervention
Figure 1: Flowchart of study participation.
Most of the women had some college education and
were Caucasian (Table 1). The median body mass index
was 29-30 kg/m2. There were no differences by intervention
in age, education, BMI, race, or Hispanic ethnicity (P >
0.10). Selected eligibility data and endocrine results are also
displayed in Table 1. On average, the participants had 5-6
menses in the most recent 12 months without hormonal
intervention before enrollment.
The preintervention AMH concentration did not vary
between the intervention arms (P = 0.79, Table 2), nor
were there differences in AMH by intervention at the other
two time points (P > 0.80). The change in the AMH
concentration was not clinically relevant by intervention
arm. AMH increased by 0.02 and decreased by 0.005 ng/mL
in the true and sham arms, respectively, after the intervention
(P > 0.30). AMH decreased by 0.05 and increased by
0.01 ng/mL in the true and sham arms, respectively, after the
entire 5-month protocol (data not displayed, P > 0.40).
No differences were detected between the true and
sham acupuncture interventions in terms of the relation-
ship between AMH concentration and both ovulation and
menses. There was no correlation between the pre- and
postintervention change in AMH level and the ovula-
tory frequency or menstrual cycle frequency in either the
acupuncture arm (P > 0.30) or the sham arm (P >
0.50). Similarly, there were no corresponding correlations
when the timeframe was expanded to include the entire 5
months of the protocol (P > 0.30). The preintervention
AMH concentration did not predict who would become a
“responder” to the true acupuncture, defined as at least a
60% monthly ovulation rate over the entire study timeframe
(P = 0.29). The change in the AMH concentration over
the 5-month protocol was not associated with being a
“responder” in the true acupuncture arm (P = 0.66).
Combining the intervention arms in Table 3, the prein-
tervention AMH concentration was significantly inversely
related to both the ovulatory frequency during the trial
(Spearman’s r = −0.54, P < 0.001) and the frequency
of menses during the trial (Spearman’s r = −0.50, P <
0.001). Combining the intervention arms, there was no
correlation between the change in AMH level either during
the intervention only or the entire 5-month trial and the
ovulatory frequency or menstrual cycle frequency (P > 0.55).
Age approached statistical significance in terms of being
associated with the preintervention AMH levels in this PCOS
cohort (P = 0.053). Figure 2 displays the log-transformed
AMH concentration by age with a line-of-best-fit, which
corresponds to the equation





The AMH concentration by age was significantly higher
in the PCOS cohort (P < 0.0001) in comparison to a cohort
of 17,120 women from infertility clinics across the USA [6].
The comparison cohort is graphed as a heavy red line in
Figure 3. For comparison purposes, the equation underlying
the line-of-best-fit for this cohort from Seifer et al’s is





AMH was not related to BMI (Spearman’s P = 0.45).
The median AMH by BMI tier is as follows: 6.4 for 20.0–
24.9 BMI, 8.4 for 25.0–29.9 BMI, 7.6 for 30.0–34.5 BMI, 7.5
for 35.0–39.9 BMI, and 4.3 for 40.0–44.9 BMI.
4. Discussion
4.1. Summary. Our investigation revealed that this acupunc-
ture protocol and this sham protocol individually did not sig-
nificantly alter the serum AMH concentrations in this cohort
of women with PCOS. Combining the two protocols, the pre-
intervention AMH concentration was positively correlated
with both the ovulation frequency and the menstrual cycle
frequency during the 5-month clinical trial protocol (P <
0.0001). The AMH concentration was significantly higher
4 Evidence-Based Complementary and Alternative Medicine
Table 1: Participant demographics and biochemical data by intervention arm.
Factor True acupuncture (n = 32) Sham acupuncture (n = 39) P value
Age: median (IQR) 27.5 (22–33) 25 (23–29) 0.14
Education: n (%)
HS or less 2 (6%) 3 (8%) 0.89
Some college 14 (44%) 15 (38%)
College degree 7 (22%) 13 (33%)
More than college 9 (28%) 8 (21%)
Body mass index: Median (IQR) 29.3 (23.5–36.3) 29.9 (24.4–34.9) 0.99
Race: n (%)
Caucasian 25 (78%) 32 (82%) 0.67
African-American 3 (9%) 4 (10%)
Other 4 (13%) 3 (8%)
Hispanic: n (%) 0 (0%) 3 (8%) 0.11
Menses in the 12 months prior to enrollment
without hormonal medications
6 (3.5–7) 5 (3–7) 0.31
Fasting plasma glucose (mg/dL): median (IQR) 93 (88–96) 94 (89–98) 0.62
Fasting serum insulin (mIU/mL): median (IQR) 7.8 (3.5–13.3) 6.9 (2.7–10.9) 0.46
TSH (uIU/mL): median (IQR) 1.36 (0.84–1.91) 1.51 (1.07–2.02) 0.50
17 OHP (ng/dL): median (IQR) 121 (81–148) 124 (76–150) 0.62
HbA1C: median (IQR) 5.3 (5.1–5.5) 5.3 (5.1–5.6) 0.34
DHEAS (µg/dL): median (IQR) 129 (101–231) 174 (126–214) 0.75
Free testosterone (pg/mL): median (IQR) 11.3 (7.6–14.6) 11.1 (7.6–18.7) 0.67
SHBG (nmol/L): median (IQR) 33.1 (21.7–58.0) 33.5 (23.0–53.4) 0.90
Table 2: Longitudinal AMH concentrations (ng/mL) in women with PCOS by intervention: median (interquartile range).
Intervention arm Preintervention baseline Postintervention P valuea Three-month follow-up P valuea
True acupuncture (n = 32) 6.5 (4.4–9.9) 6.4 (4.5–10.9) 0.36 6.2 (5.0–9.2) 0.57
Sham acupuncture (n = 39) 7.4 (4.1–9.6) 6.4 (4.5–9.0) 0.63 5.8 (4.2–10.4) 0.43
P valueb 0.79 0.90 0.84
aOne-sided test for a decline in AMH since the preintervention value.
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Figure 2: Preintervention log-transformed AMH concentration by
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AMH baseline
Figure 3: Preintervention AMH concentration (ng/mL) by age in
PCOS women and compared to Seifer et al.’s [6] population of
17,120 women.
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Table 3: Correlation between AMH concentrations and both ovu-












Change in AMH post- versus
preintervention
−0.02 (0.90) −0.07 (0.58)
Change in AMH 3 month
follow-up versus preintervention
0.08 (0.53) −0.01 (0.92)
∗
P ≤ 0.05.
across all ages in the PCOS cohort in comparison to a very
large cohort of fertility clinic patients (P < 0.001).
4.2. Comparison to Relevant Literature. Low serum AMH
levels have been shown to be predictive of infertility
treatment in women without PCOS. Lower serum AMH
concentrations during assisted reproduction treatment are
strongly associated with a reduced oocyte yield and low
oocyte quality [18, 19]. For women with PCOS who had
AMH levels that were 2 to 3 times the level produced
by normal ovaries [20] the opposite appeared to be true
in that women with high serum AMH predicted poor
response to treatment [21, 22]. It was not surprising that
the AMH concentrations were not associated with the real or
sham acupuncture protocols, as the underlying randomized
clinical trial found that there was no difference in the
ovulation rate by intervention arm [13]. We predicted a
decline in the AMH concentrations toward non-PCOS levels
in women who responded to the intervention; however, any
decline was not statistically significant. In one study with
65 PCOS cases, serum AMH concentrations declined an
average of 7% after six months of metformin treatment (P <
0.01) [23]. A 7% decline in our measurements would have
corresponded to a half point.
Preintervention serum AMH concentrations predicted
success in terms of regular ovulation and menses, as has
also been reported in women without PCOS [18, 19]. This
finding suggests that AMH levels could serve as a marker
of the likelihood of PCOS resolution without treatment or
may support the underlying clinical trial’s original report
suggesting that both interventions provided benefit [13].
One prior report did find that baseline AMH levels in women
with PCOS predicted the response to treatment; in their case
the treatment arms were laparoscopic ovarian drilling and
clomiphene citrate (P < 0.01, [24]).
As expected, there was an inverse association between
age and AMH concentration, as reported by others [5, 23,
25, 26]. If we were to impose a linear structure on our
AMH values in order to compare to the literature, then the
slope of the AMH/age association in our PCOS cohort was
−0.19. This slope was somewhat steeper than a prior report
(−0.11 [25]) and was surprisingly similar to the slope of the
AMH decline among women without PCOS who were seen
in a fertility clinic (−0.15) [6]. This implies that the rate of
decline in AMH as a woman ages is similar in both PCOS
and non-PCOS populations. One area of future research,
unrelated to the acupuncture intervention, is a description
of the AMH concentrations in women with PCOS as they
progress through the menopausal transition to their final
menstrual period.
Most of the prior research did not find an association
between AMH and BMI in women with PCOS [9, 23, 25],
although one publication did report an inverse correlation
[26]. The varying results in the literature on this item may be
due to different presentations of PCOS as reported by Lin et
al. in 2011 [26] or may be due to serum versus plasma AMH
measurements.
4.3. Strengths and Limitations. The findings are limited by
the fact that the acupuncture protocol did not allow for
individualization, thus the findings are not reflective of “real
world” acupuncture practice. Therefore, the interpretation
of the results is limited to this particular acupuncture (and
sham) protocol. There was no consideration of phenotypes
within the PCOS diagnostic framework, as was investigated
by others [26]. The sham procedure might not have been
inert, as the underlying clinical trial results implied a benefit
to both the true and sham acupuncture groups. Thus there
may be a true impact of acupuncture on AMH, which
might have been observed if the comparison had been an
observation-only cohort. Our sample was also limited to
women with longitudinal AMH samples, thus women who
became pregnant or dropped out of the study during the 2
months of the intervention (n = 13) could not be included,
and this may have influenced our findings if those women
had lower AMH levels than the median of the population
analyzed.
A strength of this study is the RCT design, with its
prospective data collection and blinding of the intervention.
This is the only clinical trial of acupuncture to measure
AMH in women and one of only a few reports [23, 24]
with longitudinal assessments of AMH in a cohort of
women with PCOS. The diagnosis of PCOS was conducted
objectively through this study on all women, thus avoiding
bias at the time of the eligibility assessment. Ovulation
was measured objectively through serum progesterone and
urinary pregnanediol glucuronide, as reported previously
[13]. This study included PCOS women from the general
community (approximately 40% had not been diagnosed
with PCOS prior to study enrollment) as opposed to a clinic
population with potentially more severe disease. The cohort
represented a wide range of ages and BMI, which improves
the generalizability of our findings.
4.4. External Validity. These findings are applicable to
women with PCOS as diagnosed with NICHD criteria. As
stated above, the interpretation of the results is limited to this
particular acupuncture (and sham) protocol.
4.5. Clinical Significance. In women without PCOS, AMH
has been increasingly used as a marker of ovarian reserve
[27] and has been shown to be a potential predictor of
6 Evidence-Based Complementary and Alternative Medicine
success in assisted reproduction [18, 19]. AMH has been
shown to be elevated in women with PCOS [20] and may
become a useful marker of PCOS. Our study showed elevated
levels of AMH, consistent with other reports [5, 18, 20, 21],
and it appears that this elevation may be an arithmetic
deviation (as opposed to a multiplicative relationship) that
is fairly consistent over a wide age range. Importantly,
preintervention AMH levels were associated with ovulatory
rates during the course of the trial, lending further evidence
that AMH could become a potential marker for severity of
disease in women with PCOS.
AMH concentrations were not associated with the real
or sham acupuncture protocols consistent with the findings
from the underlying randomized clinical trial which found
no difference in the ovulation rate by intervention arm [13].
Thus, we were unable to define clinical or serum markers
associated with successful treatment with this acupuncture
protocol in women with PCOS. More research is indicated
in this particular area of fertility treatment of women with
PCOS.
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